Peter J Goebell, Edwin Hermann, Ulrich Kube, Christian Doehn, Norbert Marschner, Anja Dietel, Katja Blumenstengel, Marc-Oliver Grimm, Michael Scheffler, Anja Rogler, Lothar Bergmann
BACKGROUND: This study assessed the quality of life (QoL) and the implication of time effort of everolimus treatment in patients with metastatic renal cell carcinoma (mRCC). METHODS: Adult patients with mRCC were eligible for everolimus treatment after first-line vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors or bevacizumab therapy. The primary end-point, QoL, was assessed by means of the NCCN-FACT FKSI-19 questionnaire. RESULTS: In total, 202 patients (24% of female patients; median age, 71 years) were evaluable for QoL analyses...
January 19, 2019: Oncology Research and Treatment